- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: International Journal of Molecular Sciences ; 22 (2021), 19. - Art.-Nr. 10482. - ISSN 1661-6596. - eISSN 1422-0067
- Keyword
-
Akute myeloische Leukämie
Core Binding Factors
Immuntherapie
Überleben
- Event
-
Veröffentlichung
- (where)
-
Ulm
- (who)
-
Universität Ulm
- (when)
-
2021
- Creator
-
Greiner, Jochen
Brown, Elliott
Bullinger, Lars
Hills, Robert K.
Morris, Vanessa
Döhner, Hartmut
Mills, Ken I.
Guinn, Barbara-ann
- DOI
-
10.18725/OPARU-50696
- URN
-
urn:nbn:de:bsz:289-oparu-50772-6
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:48 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Greiner, Jochen
- Brown, Elliott
- Bullinger, Lars
- Hills, Robert K.
- Morris, Vanessa
- Döhner, Hartmut
- Mills, Ken I.
- Guinn, Barbara-ann
- Universität Ulm
Time of origin
- 2021
Other Objects (12)
Identification of CDX2 targets in acute myeloid leukaemia
Loss of heterozygosity in acute myeloid leukaemia with normal karyotype
Detection of DNMT3A R882 mutations in patients with acute myeloid leukaemia
Characterization of the role of the CDX2 homeodomain in acute myeloid leukaemia
Functional characterisation of Enhancer of Zeste-Homologue 2 (EZH2) in acute myeloid leukaemia
Targeted siRNA carrier systems for the treatment of acute myeloid leukaemia (AML)
Single cell metabolic multiomics to identify vulnerabilities in acute myeloid leukaemia stem cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Characterisation of hypomethylating agent/IAP antagonist-induced cell death in acute myeloid leukaemia cells
Targeting acute myeloid leukaemia with the small molecule inhibitors of the Myb/p300 interaction
VEGF - a novel therapeutic target in central nervous system acute lymphoblastic leukaemia
Single stem cell clones of an acute myeloid leukaemia patient display functional heterogeneity in vivo
Identification of CDX2 targets in acute myeloid leukaemia
Loss of heterozygosity in acute myeloid leukaemia with normal karyotype
Detection of DNMT3A R882 mutations in patients with acute myeloid leukaemia
Characterization of the role of the CDX2 homeodomain in acute myeloid leukaemia
Functional characterisation of Enhancer of Zeste-Homologue 2 (EZH2) in acute myeloid leukaemia
Targeted siRNA carrier systems for the treatment of acute myeloid leukaemia (AML)
Single cell metabolic multiomics to identify vulnerabilities in acute myeloid leukaemia stem cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Characterisation of hypomethylating agent/IAP antagonist-induced cell death in acute myeloid leukaemia cells
Targeting acute myeloid leukaemia with the small molecule inhibitors of the Myb/p300 interaction
VEGF - a novel therapeutic target in central nervous system acute lymphoblastic leukaemia
Single stem cell clones of an acute myeloid leukaemia patient display functional heterogeneity in vivo
Identification of CDX2 targets in acute myeloid leukaemia
Loss of heterozygosity in acute myeloid leukaemia with normal karyotype
Detection of DNMT3A R882 mutations in patients with acute myeloid leukaemia
Characterization of the role of the CDX2 homeodomain in acute myeloid leukaemia
Functional characterisation of Enhancer of Zeste-Homologue 2 (EZH2) in acute myeloid leukaemia
Targeted siRNA carrier systems for the treatment of acute myeloid leukaemia (AML)
Single cell metabolic multiomics to identify vulnerabilities in acute myeloid leukaemia stem cells
Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
Characterisation of hypomethylating agent/IAP antagonist-induced cell death in acute myeloid leukaemia cells
Targeting acute myeloid leukaemia with the small molecule inhibitors of the Myb/p300 interaction
VEGF - a novel therapeutic target in central nervous system acute lymphoblastic leukaemia